Skip to main content

Table 4 The differences of urine NGAL and MMP-9 between the control and CKD subgroups

From: Identification of urine neutrophil gelatinase-associated lipocalin molecular forms and their association with different urinary diseases in cats

Parameter

Control

(n = 12)

Stage 2

(n = 25)

Stage 3

(n = 19)

Stage 4

(n = 11)

p

uNGAL (ng/ml) d

0.5 (0.3–0.6) a, b n = 12

0.3 (0.2–0.5) a

n = 23

0.5 (0.3–0.9) b

n = 18

0.6 (0.3–1.2) b

n = 11

0.030*

UNCR (10− 6) d

0.17 (0.1–0.3) a

n = 12

0.17 (0.1–0.5) a

n = 23

0.605 (0.3–1.4) b

n = 18

1.33 (0.9–2.7) c

n = 11

< 0.001**

NGAL Monomer e

0% (0/12)

20% (5/25)

63.2% (12/19)

81.8% (9/11)

< 0.001**

NGAL Dimer e

0% (0/12)

20% (5/25)

0% (0/19)

0% (0/11)

0.643

NGAL/MMP-9 e

58.3% (7/12)

60% (15/25)

84.2% (16/19)

90.9% (10/11)

0.102

  1. The different superscripts (a, b, c) indicate various significant differences
  2. dData are medians (IQR) and compared by the Kruskal-Wallis test (p < 0.05 indicated significant difference) and post hoc by Dunn’s test.
  3. eFisher’s exact test are used to compare the category data and presented in%.
  4. uNGAL Urine NGAL, UNCR Urine NGAL-to-creatinine ratio